Share

Case Study

$15.8 Million in Lab Savings. Less Than Two Years. One Health System’s Story.

Most health systems assume they’re getting reasonable pricing on their lab contracts. Some have run their own analyses. A few have dedicated supply chain teams spending months on vendor reviews.

One large national health system with hospitals spread across dozens of states did all of that. And still left tens of millions of dollars on the table.

Key Takeaways

  • $15.8M in verified lab savings achieved in under two years
  • $11.2M saved through reagent and service contract optimization across 9 lab categories
  • $4.6M in capital equipment savings from an often-overlooked opportunity
  • $2M+ in additional savings opportunities are currently in progress
  • 350+ hospital partners contribute benchmark data that has helped deliver $250M+ in documented client savings

That changed when they partnered with the hc1 Source IQ™ team. In under two years, their labs have captured over $15.8 million in verified savings across reagent contracts, service agreements, and capital equipment. Not projected. Not modeled. Completed.

$15.8M

Total verified savings

350+

Hospital partners in the benchmark network

<2 yrs

Time to capture results


The Organization

Large health systems negotiating without market-wide benchmark data consistently pay more than necessary, even when their internal teams are skilled and diligent. This health system operates hundreds of facilities across the country: acute care hospitals, behavioral health centers, freestanding emergency departments, and ambulatory locations. Lab supply spend at that scale accumulates fast. And at that scale, even small gaps between current pricing and true market benchmarks translate into millions of dollars left behind every year.

The challenge is knowing where those gaps actually exist, and having the category expertise to act before a contract window closes.


The hc1 Advantage: Network Scale No Individual System Can Match

hc1 works with 350+ hospital partners across the country, with over $250 million in total documented savings delivered across its client base. That network creates a category-level benchmark database that no individual organization, regardless of size or sophistication, can build from its own data alone. When a health system engages the hc1 Source IQ team, they are not getting a software tool pointed at their spend. They are getting visibility into what the entire market is actually paying, by category, by vendor, by contract structure.

That is the structural advantage. And it is the reason results like this are possible.


The Challenge: Good Pricing Is Not the Same as Great Pricing

This organization is sophisticated. Their supply chain and lab teams already negotiated contracts and tracked spending carefully. On the surface, many of their vendor agreements looked competitive.

But there is a difference between pricing that looks good in isolation and pricing that is elite relative to the actual market.

That gap is exactly where hc1 operates. The Source IQ team works with lab and supply chain data across hundreds of health systems, giving them category-level benchmarks that no individual organization can build from their own data alone. When this health system brought hc1 in to take a closer look, what came back was a detailed picture of where real savings were sitting, across more categories than anyone anticipated.

The key factor on the client side: they were open to it. When the analysis pointed to a new direction, their team was willing to act.


What the Savings Actually Look Like

The results span two distinct types of savings, which is part of what makes this story different.

Reagent & Service Contracts

$11.2 Million

The bulk of the savings came from renegotiating and optimizing reagent and service contracts across major lab categories. Chemistry and immunoassay represented the single largest opportunity, a category where annual spend runs into the tens of millions and where even modest pricing improvements generate outsized returns.

The categories where hc1 identified and captured savings include:

  • Chemistry and immunoassay
  • Molecular diagnostics
  • Rapid molecular testing
  • Blood banking
  • Hematology
  • Reference laboratory services
  • Rapid kits and point-of-care testing
  • Quality control supplies
  • Microbiology

Across these categories, savings were not uniform. Some came from contract renegotiations as existing agreements came up for renewal. Others came from identifying vendors willing to compete for the health system’s business at pricing benchmarks their current supplier had not offered. In the case of reference lab services alone, the team identified and locked in over $600,000 in annual savings against a spend base where this organization already believed their pricing was strong.

That is the hc1 benchmark in action. You can be a good negotiator and still not know what elite looks like.

Capital Equipment

$4.6 Million

Most health systems leave capital savings behind entirely. Here is why: lab supply chain conversations typically center on reagents and service contracts. Capital equipment, including analyzers, instruments, and high-value systems, is treated as a separate procurement process handled outside of traditional supply chain optimization. The result is that instrument pricing almost never gets subjected to the same benchmark rigor as consumable spend.

The hc1 Source IQ team operates across both. And here, that extended view produced $4.6 million in capital equipment savings, with hematology and chemistry representing the largest opportunities. A significant portion came from blood banking capital investment as well.

Total Verified Savings

$15.8 Million

Combined, this health system has completed over $15.8 million in savings across both reagent and capital categories in under two years. Those savings flow through corporate contracts that benefit every facility in the system, regardless of location. And they are not done. Additional savings in distribution and supply contracts are tracking toward another $2 million as current engagements continue.


Why Results Came in Under Two Years, Not Five

Health systems that engage hc1 Source IQ typically see meaningful savings in the first contract cycle, not after years of internal analysis. The reason is twofold: benchmark data that already exists at network scale, and a client team willing to act on what the data shows.

An individual health system negotiating alone is working without full market visibility. They know what they pay. They do not know what 350+ other systems pay for the same category with the same vendor. hc1 does. That intelligence gap is the difference between reasonable pricing and elite pricing, and it cannot be closed by adding more internal headcount or better internal software.

The second factor is timing. Lab supply savings are not available in equal measure at all times. Contracts have terms. Vendor relationships have renewal windows. The organizations that capture the most savings are the ones that move when a window opens.

This health system moved. Their team was responsive to recommendations, willing to renegotiate or transition to a new vendor when the analysis supported it, and trusted the process. That trust was not blind. The hc1 team brought specific data, category expertise, and a clear recommendation at each decision point. But the client had to be willing to act on it.

That combination of hc1’s benchmark intelligence and the client’s responsiveness is why $15.8 million in savings came together in under two years rather than over five.


Why DIY Lab Supply Chain Optimization Has a Ceiling

DIY lab supply chain optimization, whether through internal analytics teams or general-purpose software, consistently underperforms against a dedicated benchmarking partner. The ceiling is not effort or intention. It is data. An organization can build a sophisticated internal tool and still not know what its peer systems are actually paying, what a specific vendor’s real pricing floor is, or which categories have remaining room in the current contract cycle.

The hc1 Source IQ team works alongside your team as an extension of your supply chain function. The platform provides the analytical infrastructure. The people provide the expertise, the market intelligence, and the hands-on support to turn analysis into signed agreements and documented savings. That combination of proprietary benchmark data plus category experts who have negotiated these contracts hundreds of times is what creates outcomes that internal teams and software alone cannot replicate.

At this health system, that combination produced results that neither data alone nor internal team capacity alone would have generated on the same timeline.


What Your Organization Could Capture

The health system in this case study had strong internal supply chain capabilities and already believed their pricing was competitive. They still found $15.8 million in savings that had not been captured.

That pattern holds across organizations of every size. The gap between current pricing and elite-tier benchmarks exists whether you have 5 hospitals or 100. The categories where savings live, including chemistry, molecular, and capital equipment, are consistent. What varies is how much is available and how quickly it can be captured based on your current contract landscape.

The only way to know what your number looks like is to look.

hc1 offers a complimentary savings assessment for health systems ready to find out.

No obligation. No upfront cost. Just a clear picture of where your lab supply spend stands relative to benchmark, and what a partnership with the hc1 Source IQ team could deliver.

Request Your Free Assessment


Frequently Asked Questions

How long does it take to see lab supply chain savings with hc1?+

Most health systems begin seeing verified savings within the first contract renewal cycle. The national health system in this case study captured $6 million in completed savings in 2025 and $9.8 million through May 2026, meaningful results in under two years, driven by benchmark-informed negotiations and a client team ready to act.

Is DIY lab supply chain optimization worth it?+

Internal analytics can surface spending patterns, but they cannot close the benchmark gap. Knowing what you pay is not the same as knowing what 500 other health systems pay for the same contract. Without network-scale benchmarking, even sophisticated internal teams negotiate without full market visibility and consistently leave savings behind.

How does capital equipment fit into lab supply chain savings?+

Capital equipment, including analyzers, instruments, and high-value lab systems, is typically procured through a separate process from reagent and service contracts, which means it rarely receives the same benchmarking rigor. hc1 Source IQ applies the same market intelligence to instrument procurement, and in this engagement that extended view produced $4.6 million in savings that would otherwise have been left on the table.

What does an hc1 lab savings assessment include?+

The complimentary savings assessment reviews your current lab supply spend against hc1’s category-level benchmarks across reagents, service contracts, and capital equipment. It identifies where your pricing sits relative to the market and estimates what a Source IQ engagement could deliver, with no obligation and no upfront cost.

By Sherri Ozawa, MSN, RN
Share

Clinical Strategy

The ANA Has Recognized PBM Nursing as a Specialty. Here Is What Health Systems Need to Do Now.

On June 17, 2026, the American Nurses Association Board of Directors formally recognized Patient Blood Management (PBM) nursing as a nursing specialty, approved the submitted PBM Nursing Scope of Practice Statement, and acknowledged the specialty standards and accompanying competencies.

This is not a symbolic designation. It creates a formal career pathway for PBM nurses, a defined credentialing framework, and a clearer standard against which health systems will be measured. The question is not whether to respond. It is how quickly and how well.

Key Takeaways

  • The ANA formally recognized Patient Blood Management nursing as a nursing specialty, approving its scope of practice, standards, and competencies
  • Fewer than 100 U.S. hospitals currently operate formal anemia management programs, leaving most health systems without the infrastructure the new specialty demands
  • AI-powered clinical intelligence platforms like hc1 Clinical IQ™ can help health systems close that gap, reducing transfusion rates, avoiding complications, and generating documented ROI.
  • Health systems that build robust PBM programs now will gain a competitive advantage in talent recruitment, accreditation, and payer conversations

Why This Recognition Matters

PBM nursing recognition gives health systems a clear framework for building, credentialing, and sustaining PBM nursing roles. That matters because the scale of the problem demands a specialized, accountable response.

30-40%

of all blood transfusions remain unnecessary, excessive, or avoidable

40%

of major surgery patients arrive anemic, the most common indication for transfusion

<100

U.S. hospitals have formal anemia management programs today

Patient Blood Management is defined by the Society for the Advancement of Patient Blood Management (SABM) as a patient-centered, systematic, evidence-based approach to improving patient outcomes by managing and preserving the patient’s own blood, while promoting patient safety and empowerment. That definition has guided clinical practice for years. What has been missing is the professional infrastructure to match it. The ANA’s recognition begins to provide that infrastructure.

PBM nurses are positioned to address each of these realities directly. But without the data, technology, and institutional support to act at scale, even highly skilled PBM professionals can only move so far.


The Infrastructure Gap Most Health Systems Have Not Closed

Across the United States, fewer than 100 hospitals have formal anemia management programs, according to industry estimates. Most health systems that have formed PBM committees still rely on manual care coordination, fragmented internal data, and reactive transfusion monitoring – reviewing what happened rather than preventing what is about to.

The barriers are predictable. Clinicians are stretched thin. Data lives in disconnected systems. Building a sustainable program infrastructure takes time and expertise that most organizations cannot spare. Many committees do the minimum: monitoring blood component spend and utilization while the most significant drivers of transfusion overuse go unaddressed.


How hc1 Clinical IQ Supports the PBM Nursing Specialty

hc1 Clinical IQ empowers clinical and quality leaders to reduce practice variation and close care gaps at scale. The platform surfaces risk, automates workflows, and connects care teams with recognized PBM clinical experts. Two capabilities are directly relevant to PBM nursing programs.

hc1 Patient Blood Management

A Comprehensive Program Approach

hc1’s comprehensive PBM solution combines benchmarking and analytics with hands-on support from internationally recognized clinical experts. hc1 has implemented PBM programs at more than 450 hospitals, consistently reducing blood use by 20+%.

The approach is built on five fundamentals:

  • Establishing a clinically driven, multidisciplinary PBM program infrastructure
  • Developing and distributing meaningful PBM reports at the hospital, specialty, and provider level
  • Implementing evidence-based transfusion guidelines with clinical decision support
  • Rolling out ongoing, customized clinical education and awareness campaigns
  • Implementing strategies to improve anemia recognition, management, and blood loss minimization

These fundamentals are not theoretical. They are the operational backbone of programs already running – and already producing results – across hundreds of health systems.

Automated Anemia Management

hc1’s patented, EHR-integrated MyBloodHealth platform addresses one of the most persistent gaps in perioperative care: identifying and treating anemic patients before they reach the operating room.

MyBloodHealth runs continuously through EHR integration, automatically flagging surgical and obstetric patients with evidence of anemia, triaging by urgency, and generating individualized care plans for provider review. This automated approach allows providers to treat four times more patients than manual processes allow.

Through 2024, 194,520 patients at 70 U.S. hospitals were automatically enrolled in MyBloodHealth-powered programs (hc1 internal data, 2024). Among treated anemic patients, outcomes included an 83% reduction in transfusion rates and a 91% reduction in readmission rates.

Together, these capabilities support 75% of the PBM accreditation measures set by The Joint Commission and AABB – a direct alignment with the professional standards the ANA has now formalized.


Documented Outcomes Across 350+ Health Systems

hc1 Clinical IQ’s PBM outcomes are documented performance, not projections.

  • $120 million-plus in blood acquisition cost savings through the Comprehensive PBM solution
  • 260% ROI over three years
  • 8,000-plus blood transfusion complications avoided
  • 1,900-plus transfusion-associated deaths prevented

The Clinical IQ Impact

One Pennsylvania health system implemented hc1’s comprehensive PBM program in early 2022. Within nine months, the system enrolled 2,241 patients, identified 651 anemic patients, and achieved $330,000 in blood acquisition cost savings – an 18% cost reduction. Monthly margin improvement grew from an initial projection of $10,000 to $28,000 and continued climbing.


What This Means for Health System Strategy

The ANA’s recognition creates a defined professional identity for PBM nurses and raises the bar for the health systems that employ them. For executives, the strategic implications are concrete.

Recruitment and retention of PBM-specialized nursing talent will become a competitive differentiator.
Accreditation programs aligned with PBM standards will carry growing weight in quality metrics and payer conversations.
Health systems without robust PBM infrastructure will face increasing exposure to avoidable costs, complications, and care variation.

hc1 Clinical IQ is designed to support that infrastructure directly. The platform gives PBM nurses the intelligence they need to work at the full scope of their specialty, and gives health system leaders the measurable outcomes that accreditation and performance standards require.


Frequently Asked Questions

What does ANA recognition of PBM nursing mean for health systems?+

The ANA’s June 2026 recognition formally defines the scope of practice, competency standards, and career pathway for PBM nurses. For health systems, it creates a clearer framework for credentialing PBM nursing roles and a stronger mandate to build the program infrastructure that specialty practice requires.

How many U.S. hospitals have a formal PBM program?+

Industry estimates put the number at fewer than 100 hospitals with formal anemia management programs. Most health systems that have formed PBM committees still rely on manual processes and reactive monitoring rather than proactive, data-driven management.

What is the ROI of a Patient Blood Management program?+

hc1 Clinical IQ’s documented outcomes include 260% ROI over three years, $120 million-plus in blood acquisition cost savings, and $250 million-plus in total savings across 300 health systems. Individual health system results vary based on baseline utilization, program scope, and implementation depth.

What is the difference between a PBM program and a transfusion committee?+

A transfusion committee typically reviews blood component spend and utilization retrospectively. A full PBM program adds proactive anemia screening, evidence-based transfusion guidelines with clinical decision support, provider-level reporting, and structured education – addressing the root causes of transfusion overuse rather than monitoring after the fact.

How does hc1 Clinical IQ support PBM accreditation?+

hc1 Clinical IQ’s capabilities support 75% of the PBM accreditation measures set by The Joint Commission and AABB. This includes benchmarking, clinical decision support, and automated anemia management through the MyBloodHealth platform.


Ready to assess where your cPBM program stands?

hc1 Clinical IQ has helped hundreds of health systems build, scale, and sustain PBM programs with documented clinical and financial results. No obligation. Just a clear picture of where your program stands and what is possible.

Request Your Free Assessment

For more on the PBM nursing specialty and the broader movement advancing patient blood safety, visit SABM (sabm.org) and World Anemia Awareness (worldanemiaawareness.com).